Status:
COMPLETED
A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)
Lead Sponsor:
Gilead Sciences
Conditions:
HIV
Eligibility:
All Genders
18+ years
Brief Summary
This study will evaluate HIV-1 RNA and the presence or absence of resistance at baseline and following seroconversion, assess the frequency of HIV-1 screening and screening method(s) used for evaluati...
Eligibility Criteria
Inclusion
- Participant in a FTC/TDF PrEP demonstration project or FTC/TDF for PrEP clinical study
- HIV-1 negative adults (any sex/gender, including transgender) ≥ 18 years of age at time of enrollment in the demonstration project or clinical study.
- Evidence of seroconversion while receiving FTC/TDF for PrEP
Exclusion
- This is an observational nested study and will monitor all reported seroconversions without intervention/exclusion.
Key Trial Info
Start Date :
September 2 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2017
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT01902472
Start Date
September 2 2013
End Date
October 30 2017
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gilead Sciences, Inc.
Foster City, California, United States, 94404